ALDOA and cancer: Another compound, “UM0112176”, emulates raltegravir’s mechanism of disrupting ALDOA interaction with actin, disrupting the cytoskeleton and initiating a cascade of intracellular events leading to cancer cell apoptosis (Gizak et al., 2019).